A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.
about
Treatment for inclusion body myositisHow citation distortions create unfounded authority: analysis of a citation networkImmunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse modelAutoimmune Myopathies: Where Do We Stand?Idiopathic Inflammatory Myopathies: Clinical Approach and ManagementMeasures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-Targeting protein homeostasis in sporadic inclusion body myositis.Preclinical assessment of wt GNE gene plasmid for management of hereditary inclusion body myopathy 2 (HIBM2)Immunotherapies for Immune-Mediated Myopathies: A Current PerspectiveEvidence for the use of intravenous immunoglobulins--a review of the literature.Inflammatory myopathies: clinical, diagnostic and therapeutic aspects.Reversible inflammatory and vacuolar myopathy with vitamin E deficiency in celiac disease.Treatment of sporadic inclusion body myositis with bimagrumabIntravenous immunoglobulin in neurological disease: a specialist review.EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.Diagnosis and treatment of inflammatory muscle diseases.Idiopathic inflammatory myopathies: a treatment update.Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM.Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss.Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review.Efficacy of Intravenous Immunoglobulin in Neurological Diseases.Update on idiopathic inflammatory myopathies.Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects.Intravenous immunoglobulin therapy in neurological diseases during pregnancy.Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders.Technology insight: tools for research, diagnosis and clinical assessment of treatment in idiopathic inflammatory myopathies.Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.Inclusion body myositis: a view from the Caenorhabditis elegans muscle.A rare association of early-onset inclusion body myositis, rheumatoid arthritis and autoimmune thyroiditis: a case report and literature review.Idiopathic inflammatory myopathies: current and future therapeutic options.Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis.Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis.Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee.Clinical applications of intravenous immunoglobulins in neurology.Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use.Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease.Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature.Update on treatment of inclusion body myositis.
P2860
Q24186948-BAA49560-3E78-48D2-A083-395ECDDC9C1CQ24260685-4C3466A3-793E-453D-B8F5-09B1313AA64EQ24608911-FBAE0398-3141-498F-B4EB-ACE9F7DE66EBQ26744554-291B5C51-09BB-4A1A-878F-BD74628CFD83Q26744705-B4DC17D5-AACD-489C-B008-E7083A74BC0DQ27021322-487B4BB0-42E4-4642-B64F-166ADCC1BF86Q27324564-1685C687-967D-4DAB-9285-052020267485Q30489819-ACC0DF4F-F2EE-4807-8B92-F0F052DA8A66Q30699742-D5D7E8E8-D902-42D8-8F5F-18E0B2023644Q33385332-491133B8-48E8-4559-97AA-F7D8C7F4626EQ34186450-478501DF-6B03-4554-A0A7-299A14D07538Q34351435-3DAAE291-3B14-4058-B45E-F15D5F9B8BE4Q34446951-B25FAEC6-CE12-4577-A17C-E825915F6D9DQ34574581-3817CED1-8D40-42F5-B8D2-5EB03395D636Q34597256-1E56CE87-AEDE-4FFC-9698-ADA58FD9E958Q35576424-D8A0EEBE-1544-475E-A809-D0A6ACF9C9E0Q35580539-204BC30B-A574-4372-ABEB-6B8B8084F5F0Q35991443-50C00616-DACD-44B3-B463-7926E6F71994Q36013918-B42008E2-9EDC-4EE6-8CE1-ED70787BC037Q36164823-53E8A429-9A33-4D04-B111-6A011717F8E6Q36242913-20901117-B628-44C8-8DC6-584F871C575EQ36266356-C15CB556-5617-4499-BC3E-A56AE2C325A8Q36484438-F840F6F4-18D3-4F89-ADAE-3CCD7CAD39A5Q36504363-E47BD910-5AD2-487A-8971-41FD753B42F2Q36602771-B31EC541-ACFB-47AC-8228-3331BCE1FCAAQ36602799-0DB02336-6179-46AA-B95E-2C4ECCAEE218Q36794149-E433B1D1-9A5F-44D3-8371-7A5600BB65A0Q36807476-A3601FEF-A660-47E3-8A99-F93775E303B9Q37201405-1208C6EB-76FE-4CEF-BC31-D8B6074C97F4Q37261432-B732DA48-AF7A-42A2-B5FC-DD557305E843Q37267141-E6D4035E-83B3-470D-8D63-61F09E9BE514Q37329526-628D3449-6C9D-4531-AFA5-D52699D38FECQ37366124-8D5878BC-B8A3-4C14-81B5-FCA375071C87Q37418497-A6CCAF48-C6DA-4D54-8F12-B7C287DE2EBFQ37600787-BC26ED26-5229-41D0-A7F3-99F8BD9EBEC3Q37626126-0E5437A1-8C38-4049-8DEC-E6813453B968Q37771929-7AFB7DE9-0C0D-40F7-8110-8A8068527241Q37866685-2DCCCFB7-5CCB-4E5D-8209-D950FDD075F1Q38034041-158C31A9-4553-4736-93FB-A24F149A25EAQ38093096-5F034A35-44CD-4CD0-B673-A1173EEC845B
P2860
A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A controlled study of intraven ...... isone in the treatment of IBM.
@ast
A controlled study of intraven ...... isone in the treatment of IBM.
@en
type
label
A controlled study of intraven ...... isone in the treatment of IBM.
@ast
A controlled study of intraven ...... isone in the treatment of IBM.
@en
prefLabel
A controlled study of intraven ...... isone in the treatment of IBM.
@ast
A controlled study of intraven ...... isone in the treatment of IBM.
@en
P2093
P356
P1433
P1476
A controlled study of intraven ...... isone in the treatment of IBM.
@en
P2093
P304
P356
10.1212/WNL.56.3.323
P407
P577
2001-02-01T00:00:00Z